Phacts for Pharmacists: Diabetes

1234567891011121314151617181920212223
Across
  1. 4. A condition characterized by serum glucose > 600mg/dl, elevated serum osmolality, and urine negative for ketones
  2. 7. Condition associated with symptoms of tachycardia, diaphoresis, tremors, and mental confusion
  3. 11. Is first line therapy for patients with Type 1 diabetes
  4. 12. Relative contraindication/precaution for use of DPP4 inhibitors and GLP-1 agonists
  5. 13. causes glucose dependent insulin secretion
  6. 14. Classification for patients with HbA1c between 5.7% and 6.4%
  7. 16. A medication that should be used with caution in patients with Osteoporosis
  8. 17. One of the three predominant symptoms of hyperglycemia
  9. 18. Generic name for a basal insulin
  10. 20. A GLP-1 agonist that does not have a lead-in dose
  11. 21. Known to have active metabolites
  12. 22. decreases hepatic glucose production
  13. 23. Must be administered with first bite of carbohydrate containing meal
Down
  1. 1. The only SGLT-2 inhibitor thus far not showing robust benefit for patients with CKD, HF, or reduction in MACE outcomes
  2. 2. A medication class with a U.S. box warning for heart failure NYHA Class III-IV
  3. 3. Electrolyte disorder that may be associated with SGLT-2 inhibitor therapy
  4. 5. Absolute contraindication for use of GLP-1 agonist (two words, no spaces)
  5. 6. The only DPP-4 inhibitor that does not require a renal dose adjustment
  6. 8. Generic name for a rapid acting insulin
  7. 9. A central neuropathy that effects gastric emptying
  8. 10. Causes glucose independent insulin secretion
  9. 15. The only GLP-1 agonist that is available in an oral formulation
  10. 19. Classification for patients with a HbA1c >6.5%